A Cost Effectiveness Analysis of Everolimus Plus Exemestane Compared to Chemotherapy Agents for the Treatment of ER+ HER2- Metastastic Breast Cancer in the United Kingdom

Value Health. 2014 Nov;17(7):A634. doi: 10.1016/j.jval.2014.08.2275. Epub 2014 Oct 26.

Authors

Z Polanyi¹, P Dale², M Taylor³, L Lewis³, J Glanville³, J Vieira¹, D Chandiwana¹

Affiliations

¹ Novartis Pharmaceuticals UK Limited, Camberley, UK.
² HEOR Solutions, London, UK.
³ York Health Economics Consortium, York, UK.

PMID: 27202260
DOI: 10.1016/j.jval.2014.08.2275

No abstract available